Form: Tablets
Dosage: 10 mg
Packaging: 6 vaginal tablets

Active substance: Dequalinium chloride

Form: Vaginal tablet

Dosage: Each vaginal tablet contains 10 mg dequalinium chloride


– Box with 1 blister of 6 vaginal tablets


Target group:

Women and adolescents (after the first menstruation)

The use of Fluomizin is not recommended for girls who have not had their first menstrual period and have not reached sexual maturity.

Fluomizin is a “microbicidal” product, active against all germs known to cause vaginal infections


Fluomizin is indicated

– for the treatment of vaginal infections caused by bacteria or fungi (e.g. bacterial vaginosis or candidiasis)

– or to improve asepsis prior to gynaecological operations or childbirth.


There is usually a clear improvement in discharge and inflammation within 24 to 72 hours. However, it is important to complete the treatment even when the subjective symptoms (pruritus, discharge, odour) have disappeared. Treatment for less than six days can lead to recurrence.

One vaginal tablet per day for six days.

Insert a vaginal tablet deep into the vagina every night before going to bed. To do this, lie on your back with your legs slightly bent.

It is preferable to interrupt the treatment during heavy menstruation and to resume it afterwards. (in order to avoid the drug being eliminated by the blood)

A concomitant intravaginal use of soaps, spermicides or vaginal irrigations (douches) is not recommended. Fluomizin 10 mg vaginal tablets do not interfere with the effectiveness of latex condoms. The use of non-latex condoms and other intravaginal devices is not recommended.

If necessary, Fluomizin can be used during pregnancy or while breastfeeding.

Prescription drugs. Please contact your doctor.

Notice of Trademark Infringement

Dear valued partners, customers and Dafra representatives,

It has come to our attention that unauthorized use of our company’s name and logo has been observed in various contexts in the African country Togo (https://www.dafrapharma-vet.com/). In order to avoid misunderstandings, ever misleading, we feel it is imperative to address this issue promptly and transparently.

Trademark infringement poses a significant threat not only to our brand integrity but also to the trust and credibility we have worked diligently to establish within our community. Our name and logo represent our values, quality, and commitment to excellence, and any unauthorized use undermines these principles.

We take trademark infringement seriously and are actively taking measures to address any instances of unauthorized use. This includes legal action against parties found to be infringing upon our intellectual property rights.

We urge our customers, partners, African representatives and the general public to remain vigilant and report any suspected instances of trademark infringement directly to us. Your cooperation in this matter is crucial in helping us protect our brand and preserve the integrity of our business.

As always, we remain dedicated to providing high quality medical solutions in the sub-Sahara region of Africa and maintaining the highest standards of integrity and professionalism.

Thank you for your continued support and trust in our company.

Dafra Pharma